Lacosamide Sandoz

Lacosamide, the active ingredient in Lacosamide Sandoz, is an anti‑epileptic presented as an oral formulation for oral use. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy, either as monotherapy or as adjunctive therapy.

GNH USA supplies Lacosamide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic drug that acts on neuronal sodium channels to control seizure activity. - Partial‑onset seizures: reduces seizure frequency when used alone or added to existing therapy. - Adjunctive therapy for epilepsy: improves overall seizure control in patients whose seizures are not fully managed by other medications. - Focal epilepsy: enhances seizure management as part of a comprehensive treatment plan.

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach often accompanied by an urge to vomit. - Headache: mild to moderate pain in the head region. - Blurred vision: temporary loss of visual clarity. - Diplopia: double vision occurring intermittently.

Serious or Rare Side Effects: - Cardiac arrhythmias: irregular heart rhythms that may require medical attention. - Suicidal ideation: thoughts of self‑harm that need immediate evaluation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic injury: signs of liver dysfunction including jaundice. - Anaphylaxis: acute allergic reaction with breathing difficulty. - Conduction abnormalities: PR‑interval prolongation on ECG.

When prescribing or dispensing lacosamide, consider the following safety measures. - Renal impairment: adjust dose in patients with reduced kidney function. - Cardiac disorders: monitor ECG in individuals with known conduction abnormalities. - Abrupt discontinuation: taper the dose to avoid seizure worsening. - Hepatic impairment: use caution and consider dose modification. - Pregnancy and breastfeeding: evaluate risk‑benefit due to limited data. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine): may reduce lacosamide effectiveness. - Other sodium‑channel blockers (e.g., phenytoin): can heighten central nervous system depression.

Moderate Interactions (Monitor Closely): - Co‑administration with other antiepileptics: may necessitate dose adjustments. - Antihypertensives: additive hypotensive effect may occur. - Alcohol: combined use can enhance dizziness and sedation.